Table 1 Linear regression analysis of treatment assignment and baseline BAMA HCoV antibody response magnitude as predictors of SARS-CoV-2 WA-1 microneutralization titer at D36 among 18–49 yr-old participants receiving a two-dose regimen (N = 173)

From: Prior human endemic coronavirus exposure does not affect humoral responses to SARS-CoV-2 protein vaccines

 

Coefficient

SE

P value

(Intercept)

−2.08

0.99

0.04

Low dose + AF03 (two doses schedule)

0.47

0.19

0.01

Low dose + AS03 (two doses schedule)

0.69

0.15

<0.001

High dose + AF03 (two doses schedule)

0.93

0.20

<0.001

High dose + AS03 (two doses schedule)

1.16

0.15

<0.001

High dose (two doses schedule)

−0.04

0.19

0.82

HCoV 229E spike

0.03

0.23

0.89

HCoV 229E RBD

0.25

0.26

0.32

HCoV HKU1 spike

0.34

0.28

0.22

HCoV HKU1 RBD

−0.26

0.19

0.18

HCoV NL63 spike

−0.12

0.28

0.67

HCoV NL63 RBD

0.33

0.34

0.33

HCoV OC43 spike

0.04

0.31

0.89

HCoV OC43 RBD

−0.12

0.19

0.53

  1. BAMA Binding Antibody Multiplex Assay, HCoV human coronavirus, RBD receptor binding domain, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, SE standard error, yr year
Back to article page